论文部分内容阅读
目的:对三联疗法治疗幽门螺杆菌相关慢性胃炎的疗效分析。方法:将我院自2008年10月至2010年10月收治的136例幽门螺杆菌慢性胃炎患者随机分为对照组和观察组,每组各68例。其中对照组给予“奥美拉唑+阿莫西林+甲硝唑”的三联疗法治疗,观察组给予“奥美拉唑+阿莫西林+克拉霉素”的三联疗法治疗,治疗7d为一个疗程,两个疗程内进行疗效评定。结果:观察组的治愈率(51.47%)、显效率(83.82%)和Hp转阴率(94.12%)均明显高于对照组的治愈率(23.53%)、显效率(61.76%)和Hp转阴率(76.47%),两组比较差异具有显著性(P<0.05)。观察组的不良反应发生率(20.59%)和对照组(19.12%)进行比较,两组差异无显著性(P>0.05)。结论用三联疗法治疗与幽门螺杆菌相关慢性胃炎的疗效较好,且“奥美拉唑+阿莫西林+克拉霉素”的三联疗法要明显优于“奥美拉唑+阿莫西林+甲硝唑”三联疗法,疗效肯定,Hp根除率较高,值得在临床上加以推广。
Objective: To analyze the curative effect of triple therapy on Helicobacter pylori related chronic gastritis. Methods: A total of 136 patients with Helicobacter pylori chronic gastritis treated in our hospital from October 2008 to October 2010 were randomly divided into control group and observation group, with 68 cases in each group. The control group was given triple therapy of “omeprazole + amoxicillin + metronidazole”, and the observation group was treated with triple therapy “omeprazole + amoxicillin + clarithromycin” 7d for a course of treatment, curative effect evaluation within two courses. Results: The cure rate (51.47%), markedly effective rate (83.82%) and Hp negative conversion rate (94.12%) in the observation group were significantly higher than those in the control group (23.53%, 61.76% Yin rate (76.47%), the difference between the two groups was significant (P <0.05). Adverse reactions in the observation group (20.59%) and the control group (19.12%) were compared between the two groups, the difference was not significant (P> 0.05). Conclusion The triple therapy is effective in treating chronic gastritis associated with Helicobacter pylori, and the triple therapy “omeprazole + amoxicillin + clarithromycin” is obviously better than “omeprazole + amo Xilin + metronidazole ”triple therapy, positive effect, Hp eradication rate is higher, it is worth to be promoted in the clinic.